ICD-10 Logo
ICDxICD-10 Medical Coding
ICD-10 Logo
ICDxICD-10 Medical Coding
ICD 10 CodesDiagnoses
ICD 10 CodesDiagnoses
ICD-10 Logo
ICDxICD-10 Medical Coding

Comprehensive ICD-10-CM code reference with AI-powered search capabilities.

© 2025 ICD Code Compass. All rights reserved.

Browse

  • All Chapters
  • All Categories
  • Diagnoses

Tools

  • AI Code Search
ICD-10-CM codes are maintained by the CDC and CMS. This tool is for reference purposes only.
v1.0.0
ICD-10 Guide
DiagnosesAdenocarcinoma Lung Cancer

Adenocarcinoma Lung Cancer

ICD-10 Coding for Adenocarcinoma Lung Cancer(C34.11, C78.01)

PRIMARY SPECIALTYOncology
COMPLEXITYHigh
LAST UPDATED09/15/2025
Sam Tuffun, PT, DPT
Physical Therapist | Medical Coding & Billing Contributor

Diagnosis Overview

What is Adenocarcinoma Lung Cancer?
Essential facts and insights about Adenocarcinoma Lung Cancer

Key Clinical Considerations:

  • Presence of persistent cough, hemoptysis, chest pain, or unexplained weight loss.
  • Histological confirmation of adenocarcinoma through biopsy or cytology.
  • Physical examination may reveal signs of respiratory distress or lymphadenopathy.
  • Imaging findings may include solitary pulmonary nodules, masses, or infiltrates on chest X-ray or CT scan.
  • Staging information based on the TNM classification system, including tumor size, lymph node involvement, and presence of metastasis.

Clinical Information

Clinical Criteria & Documentation Requirements

  • Complete medical history including smoking status, occupational exposures, and family history of lung cancer.
  • Specific terminology such as 'adenocarcinoma', 'non-small cell lung cancer', and 'staging' must be documented.
  • Examples include: 'Patient diagnosed with stage II adenocarcinoma of the lung based on imaging and biopsy results.'
  • Documentation must demonstrate medical necessity for diagnostic tests and treatments.
  • Quality measures may include documentation of smoking cessation counseling and follow-up imaging.

Coding Guidelines

Usage Guidelines & Examples

  • Use C34.11 for primary adenocarcinoma of the right upper lobe and C78.01 for metastatic adenocarcinoma to the lung.
  • Do not use C34.11 for small cell lung cancer or other types of lung cancer.
  • C34.90 (malignant neoplasm of unspecified part of the lung) may be used when the specific site is unknown.
  • Common errors include misclassifying adenocarcinoma as small cell lung cancer; ensure histological confirmation.
  • In complex cases, consider the patient's complete clinical picture and staging before code selection.

Code Exclusions

Important Exclusions

  • Excludes small cell lung cancer (C34.1) and other non-malignant lung conditions.
  • Alternative codes for excluded conditions include J44.9 for COPD or J98.9 for unspecified respiratory disorders.
  • Conditions are excluded to ensure accurate representation of the specific cancer type and treatment needs.
  • Common mistakes include using adenocarcinoma codes for small cell lung cancer; ensure accurate histological diagnosis.
  • Related but distinct conditions include squamous cell carcinoma and large cell carcinoma of the lung.

Related ICD-10 Codes

Primary Codes
C34.11
Malignant neoplasm of the right upper lobe of the lung
C78.01
Secondary malignant neoplasm of the lung
Ancillary Codes
Z85.118
Z08
Differential Codes
C34.9
C34.9
only when the specific location within the lung is not documented.
C34.11

Related CPT Codes

CPT codes will be available in a future update.

Specialty Focus

Primary Specialty

Oncology

Specialty Applications

  • Patients diagnosed with lung adenocarcinoma, particularly non-smokers and younger populations.
  • Patient populations include adults, with increased risk factors in those with a history of smoking or exposure to carcinogens.
  • Clinical settings include outpatient oncology clinics, inpatient hospital settings, and specialized cancer treatment centers.
  • Oncology specialty applications focus on treatment planning, chemotherapy regimens, and palliative care.
  • Treatment contexts include surgical resection, chemotherapy, and targeted therapies.

Coding Complexity

High Complexity

This diagnosis requires careful attention to:

  • Comprehensive clinical documentation
  • Accurate code selection based on clinical criteria
  • Proper exclusion considerations
  • Specialty-specific coding guidelines

Documentation

Documentation Templates

Template 1

Template: 'Patient diagnosed with adenocarcinoma of the lung based on biopsy results and imaging findings.'

Template 2

Template: 'Clinical presentation consistent with adenocarcinoma including persistent cough and weight loss.'

Template 3

Template: 'Diagnostic criteria for adenocarcinoma met as evidenced by histological analysis.'

Template 4

Template: 'Treatment plan initiated for adenocarcinoma with chemotherapy and follow-up imaging scheduled.'

Template 5

Template: 'Follow-up care for adenocarcinoma including monitoring for treatment response and side effects.'

Billing Information

Billing Considerations

  • Ensure proper documentation for billing
  • Verify code specificity requirements
  • Check for any additional codes needed
  • Review payer-specific guidelines

Common Issues

  • Insufficient clinical documentation
  • Incorrect code selection
  • Missing supporting diagnoses
  • Timing and frequency documentation

Frequently Asked Questions

What documentation is required for this diagnosis?

Detailed documentation of clinical findings, imaging results, and histological confirmation is required.

How does this differ from similar diagnoses?

Adenocarcinoma is a subtype of non-small cell lung cancer, distinguished by histological characteristics.

What are common billing considerations?

Ensure that all services provided are medically necessary and properly documented to optimize claims.

What procedures are typically associated?

Commonly associated procedures include bronchoscopy, CT-guided biopsy, and surgical resection.

Are there any quality reporting implications?

Quality measures may include tracking treatment outcomes and adherence to clinical guidelines.